Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy.

Feng Zhang Siyuan WangSiying LiangChao YuSufang LiHong ChenShu WangTiangang Zhu

Published in: Cardiology research and practice (2021)

Breast cancer patients with metabolic syndrome after completion of cancer-related comprehensive therapy suffered from subclinical myocardial dysfunction. GLS should be routinely performed to early identify subclinical myocardial damage of patients, in order to prevent the cardiotoxicity of cancer-related comprehensive therapy.

Keyphrases

metabolic syndrome
left ventricular
oxidative stress
end stage renal disease
newly diagnosed
insulin resistance
chronic kidney disease
heart failure
prognostic factors
cardiovascular disease
cell therapy
cardiovascular risk factors
patient reported outcomes